Core Insights - Loomis Sayles Small Cap Growth Fund's performance in Q4 2025 showed a return of 0.51%, underperforming the Russell 2000 Growth Index which returned 1.22% [1] - The earnings of small-cap companies are reaccelerating in 2025, aligning with previous forecasts [1] - The Fund's outlook for 2026 is optimistic regarding the economy, earnings growth, and the stock market [1] Company Highlights - Wave Life Sciences Ltd. (NASDAQ:WVE) is identified as a leading contributor to the Fund's performance, focusing on RNA-targeted therapies [2][3] - As of March 24, 2026, Wave Life Sciences Ltd. had a stock price of $11.63, with a one-month return of -20.01% and a 52-week gain of 24.75% [2] - The market capitalization of Wave Life Sciences Ltd. is reported at $2.19 billion [2] Performance and Contributions - Wave Life Sciences Ltd. was noted for publishing data on a novel obesity target, which positively impacted its stock performance during the quarter [3] - Alongside Wave Life Sciences, Establishment Labs Holdings and MACOM Technology Solutions Holdings were also highlighted as top contributors [3] Hedge Fund Interest - At the end of Q4 2025, 45 hedge fund portfolios held shares of Wave Life Sciences Ltd., an increase from 38 in the previous quarter [4] - Despite the potential of Wave Life Sciences Ltd., analysts suggest that certain AI stocks may offer greater upside potential with less downside risk [4]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported a net income of $1.23 billion and diluted earnings per share of $25.48, reflecting a significant appreciation in treasury and treasury-related assets [3][11] - The total treasury and treasury-related assets reached $2.31 billion, with shareholders' equity at $1.93 billion, indicating strong financial positioning [11][12] Business Line Data and Key Metrics Changes - The company's dual-engine model integrates clinical development with a treasury strategy focused on prediction markets, which is expected to drive long-term value [3][10] - The clinical platform, particularly Allocetra, has shown statistically significant results and a favorable safety profile, with a clear pathway toward late-stage development in osteoarthritis [9][16] Market Data and Key Metrics Changes - The prediction markets ecosystem is experiencing structural momentum, with increasing trading volumes and institutional engagement, positioning the company to capture early opportunities [12][18] - The RAIN token, as a primary digital treasury reserve asset, is expected to benefit from the growing decentralized prediction markets, enhancing long-term shareholder value [13][15] Company Strategy and Development Direction - The company aims to establish itself as a leader in a new category of public companies that combine scientific innovation with emerging financial infrastructure [10][18] - A strategic partnership with the Rain Foundation allows the company to acquire RAIN tokens at a fixed price, enhancing its capital structure and growth potential [5][8] Management's Comments on Operating Environment and Future Outlook - Management believes that the prediction markets will continue to evolve into a core layer of global financial infrastructure, validating the company's treasury strategy [4][12] - The company is optimistic about the scalability of its dual-engine model, driven by the growth of both prediction markets and its clinical programs [30][31] Other Important Information - The company announced a $21 million debt financing agreement to fund clinical development and acquire additional RAIN tokens at a discount [6][7] - A share repurchase program was approved to acquire up to $20 million of outstanding shares, reflecting confidence in the company's long-term value [8] Q&A Session Summary Question: Why is Enlivex posting large profits for 2025 despite a downturn in crypto? - The company's exposure to prediction markets, particularly the RAIN token, has led to significant valuation increases, contrasting with broader crypto market trends [20][22] Question: How to explain the market cap discount to treasury valuation? - The current market sentiment towards crypto has led to net asset value discounts, but there is hope for recovery as the prediction market ecosystem grows [23] Question: Does this change how clinical-stage companies can be financed? - The funding landscape for early-stage biotech has become more challenging, but Enlivex's model allows for self-funding through treasury asset appreciation, mitigating dilution concerns [24][25] Question: Is this a one-off outcome for prediction markets in public company earnings? - Management views this as the beginning of a broader shift towards integrating prediction markets into public company structures [26] Question: How should investors view Enlivex after these results? - Investors are likely to reassess the company's value proposition, recognizing the potential of its dual model strategy [29] Question: What are the key drivers for scaling this model? - The scalability will depend on the growth of the prediction markets ecosystem and the success of the clinical programs, with several milestones planned for the next two years [30]

Core Insights - The company's performance was negatively impacted by a 15% decline in activity from its largest customer due to manufacturing site reorganization and inventory management [1] - A net loss of six SPL clinical programs is expected in 2025 as biotech partners rationalize portfolios and conserve capital [1] - Management believes the current revenue trajectory is influenced by short-term headwinds from discontinued programs rather than a fundamental shift in technology demand [1] Business Strategy - The launch of ExPERT DTX signifies a strategic pivot aimed at capturing customers at the earliest research stages, creating a 'seamless path' to clinical scale-up [1] - Operational efficiency has improved significantly following a restructuring that reduced annual cash burn by over $16 million compared to the prior model [1] - The integration of SecurDx positions the company to address the evolving regulatory focus on off-target risk assessment in gene editing [1]

Core Insights - BullFrog AI Holdings, Inc. has launched bfARENAS, an advanced AI decision tool designed to enhance drug target discovery and clinical trial strategies, thereby creating diversified and risk-balanced R&D portfolios [1][2][3] Product Overview - bfARENAS completes the company's end-to-end AI intelligence workflow by adding a strategic decision layer, complementing existing products bfPREP and bfLEAP [3] - Unlike traditional portfolio machine learning tools, bfARENAS evaluates options through head-to-head comparisons across multiple strategic scenarios, providing trackable and explainable decisions for drug discovery and development [3][4] Key Capabilities - bfARENAS supports high-stakes portfolio and program decisions by integrating with BullFrog Data Networks, facilitating a seamless workflow from data harmonization to strategic decision support [4] - The platform allows for comparison of drug programs, targets, biomarkers, and trial designs without relying on arbitrary numerical scores, thus preserving portfolio diversity while identifying clear leaders [8] Webinar Announcement - A webinar titled "Turning AI Recommendations into Clear, Defensible Decisions" will be hosted on March 27, 2026, to discuss how bfARENAS can improve portfolio and trial strategy decisions [5][6]

Investment Rating - The report maintains a "BUY" rating for WuXi AppTec, with a target price raised to RMB133.00, indicating a potential upside of 42.0% from the current price of RMB93.68 [3][18]. Core Insights - WuXi AppTec reported a revenue growth of 15.8% YoY for 2025, with adjusted non-IFRS net profit increasing by 41.3% YoY, both figures surpassing estimates [1][2]. - Management projects 2026 revenue to reach RMB51.3-53.0 billion, with continuing operations expected to grow by 18-22% YoY [1]. - The backlog for continuing operations grew by 28.8% YoY to RMB58.0 billion, indicating strong demand for CDMO services [9]. - The company plans to increase capital expenditure to RMB6.5-7.5 billion in 2026, reflecting a commitment to global capacity expansion [9]. Financial Performance - Revenue projections for FY26E are RMB51,695 million, with a YoY growth of 13.7% [2]. - Adjusted net profit for FY26E is expected to be RMB17,930 million, reflecting a 19.9% YoY increase [2]. - The adjusted net profit margin is anticipated to remain stable, contributing to a robust financial outlook [1][9]. Valuation Metrics - The P/E ratio is projected to decrease from 17.9 in FY25A to 15.6 in FY26E, indicating improved valuation attractiveness [2][15]. - The gross profit margin is expected to improve to 48.5% in FY26E, up from 47.6% in FY25A [16]. Market Position - WuXi AppTec's market capitalization stands at RMB279,518.4 million, with a significant shareholding structure that includes 23.7% held by HK investors and 16.4% by Ge Li and concerted parties [4][5]. - The company has shown resilience in early-stage business recovery, with revenue growth in the Testing and Biology segments [9].

Group 1 - Apogee Therapeutics, Inc. has announced a public offering of 5,000,000 shares of common stock at a price of $70.00 per share, aiming for gross proceeds of approximately $350 million before expenses [1] - The offering is expected to close on March 26, 2026, pending customary closing conditions [1] - Underwriters have an option to purchase an additional 750,000 shares within 30 days at the public offering price [1] Group 2 - Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering, with Wedbush PacGrow and BTIG as lead managers [2] - An automatically effective shelf registration statement was filed with the SEC on August 12, 2024, and the offering is being made through a written prospectus [3] Group 3 - Apogee Therapeutics is focused on developing novel biologics for inflammatory and immunology markets, targeting conditions such as Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease [5] - The company's lead program, Zumilokibart (APG777), is being developed for Atopic Dermatitis, which is a significant and under-penetrated market [5] - Apogee aims to achieve best-in-class efficacy and dosing through its antibody programs, which are designed to overcome limitations of existing therapies [5]

Core Viewpoint - Codexis, Inc. (NASDAQ:CDXS) is recognized as one of the best high-risk penny stocks to buy, with analysts maintaining a positive outlook despite varying price targets [1][3]. Financial Performance - For Q4 2025, Codexis reported revenues of $38.9 million, contributing to a total of $70.4 million for the full year, reflecting an 18.7% year-over-year revenue growth [3]. - The company improved its gross margin from 56% to 64% during the same period [3]. - For 2026, Codexis anticipates revenue of $74 million at the midpoint, with expectations that most revenue will be generated in the latter half of the year [3]. Strategic Goals - The company's goals for 2026 include demonstrating proof of success to investors through contract signings and innovative licensing deals [4]. - Codexis owns the CodeEvolver platform, which aids in the discovery, development, and commercialization of novel enzymes, and the ECO Synthesis manufacturing platform for RNAi therapeutics [4].

Company Overview - Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is a clinical-stage biotechnology company focused on developing therapies for heart disease, with lead product candidates including TN-401, TN-201, and TN-301 [5]. Investment Outlook - Andy Hsieh of William Blair maintained a Buy rating on Tenaya Therapeutics, citing a positive outlook due to the company's advancing pipeline and improving regulatory clarity [1]. - Expected alignment with regulators on pivotal trial designs for TN-201 and TN-401 could serve as a major de-risking event, providing clearer approval pathways and better visibility on potential value drivers and timelines [1]. Clinical Developments - Momentum into 2026 is supported by resumed enrollment in the MyPEAK-1 study for TN-201 and positive DSMB safety feedback on TN-401, which allows for dose expansion [3]. - Early data from TN-301 is significant as it expands the platform beyond gene therapy, potentially adding a third growth pillar, with sufficient capital available to execute current plans [3]. Financial Performance - For the fourth quarter, Tenaya Therapeutics reported a GAAP EPS of -$0.12, aligning with expectations [4]. - As of December 31, 2025, the company held $100.5 million in cash, cash equivalents, and investments in marketable securities, an increase from $61.4 million at the end of December 2024, reflecting net proceeds of $55.8 million raised through a public offering [4].

Core Insights - Equillium, Inc. (NASDAQ:EQ) is recognized as one of the best high-risk penny stocks to buy, with a Buy rating and a price target of $12, indicating a potential upside of 458% from current levels [1] - The company is advancing its oral colon-targeted therapy EQ504 into Phase 1 trials for ulcerative colitis, leveraging a validated mechanism, yet the stock is trading as if it holds an unproven asset [1] - Equillium has entered a definitive securities purchase agreement with RA Capital Management to raise approximately $35 million by issuing around 18.9 million shares at $1.854 per share, providing additional capital for operations and development [2] Company Overview - Equillium, Inc. operates as a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders in the United States, targeting conditions with significant unmet medical needs [3] - The company's lead product candidate is Itolizumab (EQ001), which is part of its broader therapeutic development strategy [3]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $33 million, a 15% decline from $38.6 million in 2024 [23] - Fourth quarter revenue for 2025 was $7.3 million, down 16% from $8.7 million in Q4 2024 [23] - Core revenue for 2025 was $29.6 million, a 9% decrease from $32.5 million in 2024 [24] - Gross margin in Q4 2025 was 78%, up from 74% in Q4 2024 [26] - Total operating expenses for Q4 2025 were $16.9 million, down from $19.3 million in Q4 2024 [27] Business Line Data and Key Metrics Changes - Instrument revenue for Q4 2025 was $1.8 million, compared to $1.6 million in Q4 2024 [24] - License revenue in Q4 2025 was $2 million, down from $2.6 million in Q4 2024 [24] - PA revenue in Q4 2025 was $2.3 million, compared to $4.2 million in Q4 2024 [24] - SPL program-related revenue for 2025 was $3.4 million, down from $6.1 million in 2024 [26] Market Data and Key Metrics Changes - 47% of core business revenue was derived from SPL customers in 2025, down from 55% in 2024 [25] - The company supports 12 clinical programs across 11 SPL partners, with 5 programs expected to enter pivotal studies over the next 18 months [14][16] Company Strategy and Development Direction - The company launched the ExPERT DTx platform, aimed at enhancing early-stage research and drug discovery [6][8] - The company expects to stabilize and grow its SPL customer base despite recent headwinds [10] - The company is focused on innovation and maintaining a competitive edge in the market [10][18] Management's Comments on Operating Environment and Future Outlook - Management indicated that the challenges faced in 2025 will impact the first half of 2026, with a revenue guidance of $30 million-$32 million for 2026 [9] - Management remains optimistic about the medium-term opportunities, with multiple clinical programs progressing towards commercialization [14][18] - The company has reduced annual cash burn by over $16 million and is on a different spending trajectory [21] Other Important Information - The company ended 2025 with a strong balance sheet, having $155.6 million in cash and no debt [28] - A new CFO, Parmeet Ahuja, will join the company effective March 30 [22] Q&A Session Summary Question: Concerns about business trajectory and core revenue decline - Management clarified that the expected decline in core revenue is due to a $4 million headwind from lost customers, not a deterioration in business fundamentals [31][32] Question: Outlook for core revenues and industry demand - Management indicated that any improvement in industry demand would be upside to the current guidance, which is not contingent on external factors [36] Question: Pipeline and revenue contribution from the DTx platform - Management expects revenue from the DTx platform to begin trickling in during the second half of 2026, with significant contributions anticipated in 2027 [41][42] Question: SPL signing cadence and visibility - Management expressed confidence in signing at least three new SPLs in 2026, with ongoing discussions with potential partners [50][51] Question: SeQure contribution and royalty revenue visibility - Management expects significant year-over-year growth from SeQure Dx in 2026, with approximately $2 million in expected royalty revenue [60]